CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)

Nader Pourhassan, Ph.D







CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, providing an update on the company’s drug development pipeline targeting HIV and cancers, based on CytoDyn’s Leronlimab/PRO 140 platform.

CytoDyn’s combination therapy for HIV is expected to receive FDA approval in 2019, and potentially generating revenues by early 2020. Especially compelling is the possibility of CytoDyn’s HIV monotherapy which could get potential FDA approval the following year. CytoDyn’s monotherapy is a potential “game changer” in HIV treatment, requiring only a once-weekly injection which can be self-administered.  

Dr. Pourhassan also provides an update on CytoDyn’s portfolio of potential cancer therapies which are now entering clinical trials. 

Investor Presentation

Cytodyn presentation
Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.